The company’s study found a significant increase in binding antibodies in participants between the ages of 18 and 55, and in those 65 years and older who received a lower booster dose.
"We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine," said Mathai Mammen, Global Head of Janssen Research & Development at Johnson & Johnson. "We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination."
Moderna has also completed its submission for full approval of its COVID-19 vaccine with the FDA. Earlier this week, Pfizer's vaccine was granted full approval.